Bayer’s asundexian wins US approval to prevent repeat strokes, Reuters reports

The FDA approved asundexian, branded Sunharbo, as a once-daily treatment to prevent another stroke in patients whose previous stroke was not caused by a clot from the heart, Reuters reports. It also covers patients who had a high-risk transient ischemic attack, or “mini-stroke.” Reuters says Bayer is betting on the drug as cheaper generics erode sales of older medicines such as Xarelto.